Whereas most of the current clinical trials target the molecule VEGFα, targeting CCL2 can address the mechanisms of early leukocyte influx, leukostasis and adhesion to the retinal capillary wall in diabetes, a potentially critical upstream target for the treatment of DME. The gene discussed is VEGFA; the disease is diabetes mellitus.